IXHL

Index	-	P/E	-	EPS (ttm)	-17.18	Insider Own	0.80%	Shs Outstand	346.23M	Perf Week	-16.34%
Market Cap	1.31B	Forward P/E	4.21	EPS next Y	0.90	Insider Trans	0.00%	Shs Float	343.45M	Perf Month	3.84%
Enterprise Value	1.24B	PEG	-	EPS next Q	-0.60	Inst Own	0.37%	Short Float	0.29%	Perf Quarter	-51.69%
Income	-48.41M	P/S	-	EPS this Y	97.04%	Inst Trans	39.96%	Short Ratio	1.80	Perf Half Y	-64.62%
Sales	0.00M	P/B	0.69	EPS next Y	175.00%	ROA	-100.36%	Short Interest	0.99M	Perf YTD	-64.71%
Book/sh	5.50	P/C	17.63	EPS next 5Y	-	ROE	-117.17%	52W High	49.80 -92.39%	Perf Year	-51.41%
Cash/sh	0.22	P/FCF	-	EPS past 3/5Y	-234.70% -136.42%	ROIC	-64.32%	52W Low	2.49 52.21%	Perf 3Y	-98.36%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -29.33%	Gross Margin	-	Volatility	9.41% 9.15%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	54.21%	Oper. Margin	-	ATR (14)	0.38	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	41.56	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	43.55	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	41.56	EPS Q/Q	94.81%	SMA20	-10.04%	Beta	2.94	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	2.42%	Rel Volume	0.52	Prev Close	3.96
Employees	12	LT Debt/Eq	0.00	Earnings	Feb 13 BMO	SMA200	-61.44%	Avg Volume	552.45K	Price	3.79
IPO	Mar 02, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	286,880	Change	-4.29%

May-14-26 10:35AM	Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea (GlobeNewswire)
May-12-26 08:00AM	Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development (GlobeNewswire) -13.91%
Apr-22-26 08:00AM	Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness (GlobeNewswire) +8.49%
Mar-27-26 08:00AM	Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position (GlobeNewswire)
Mar-25-26 08:00AM	Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research (GlobeNewswire) +15.83%
08:00AM	Loading…
Mar-18-26 08:00AM	Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development (GlobeNewswire) -6.65%
Mar-17-26 08:00AM	Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Mar-12-26 08:05AM	Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -48.41%
08:00AM	Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes (GlobeNewswire)
Mar-03-26 03:24PM	Incannex Healthcare Inc. (IXHL) Implements 1-for-30 Reverse Split Effective February 26 (Insider Monkey)
Feb-25-26 09:20AM	Incannex Announces Reverse Stock Split (GlobeNewswire) -42.12%
Feb-18-26 06:35PM	Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026 (Newsfile) +8.27%
Jan-29-26 08:00AM	Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board (GlobeNewswire)
Jan-26-26 09:55AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jan-22-26 08:00AM	Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program (GlobeNewswire)
08:00AM	Loading…
Jan-15-26 08:00AM	Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards (GlobeNewswire)
Jan-14-26 08:00AM	Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026 (GlobeNewswire)
Dec-03-25 08:00AM	Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA) (GlobeNewswire) +12.68%
Dec-01-25 12:00PM	What Makes Incannex Healthcare Inc. (IXHL) a New Buy Stock (Zacks)
Nov-20-25 09:34AM	Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2026 (Newsfile)
Oct-30-25 08:00AM	Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus (GlobeNewswire) +17.78%
Oct-22-25 08:00AM	Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement (GlobeNewswire)
Aug-31-25 05:41PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Aug-26-25 08:00AM	Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder (GlobeNewswire)
Aug-22-25 08:00AM	Incannex Healthcare Authorizes $20 Million Share Repurchase Program (GlobeNewswire) +28.52%
Aug-19-25 04:29PM	Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update (Newsfile) +5.99%
Aug-17-25 01:56AM	Incannex Healthcare Inc. (IXHL) Receives Positive Patient-Reported Outcomes For IHL-42X in Obstructive Sleep Apnoea (Insider Monkey)
Aug-08-25 08:00AM	Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea (GlobeNewswire)
Jul-31-25 08:00AM	Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term (GlobeNewswire) -33.52%
Jul-30-25 08:00AM	Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X (GlobeNewswire) -17.76%
07:30AM	Loading…
Jul-25-25 07:30AM	Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo (GlobeNewswire) -35.58%
Jun-24-25 07:30AM	Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch (GlobeNewswire) +10.00%
Jun-18-25 07:30AM	Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X (GlobeNewswire)
Jun-17-25 07:30AM	Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy (GlobeNewswire) +5.53%
Jun-12-25 07:30AM	Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution (GlobeNewswire) +14.57%
Jun-03-25 07:30AM	Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program (GlobeNewswire)
May-29-25 07:30AM	Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance (GlobeNewswire)
May-28-25 04:21PM	Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 (Newsfile) -14.78%
07:00AM	Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results (GlobeNewswire)
May-20-25 07:30AM	Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution (GlobeNewswire) +20.06%
May-16-25 09:00AM	Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants (GlobeNewswire)
May-15-25 08:00AM	Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire) -61.64%
May-14-25 08:00AM	Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) (GlobeNewswire) +720.63%
Apr-03-25 07:30AM	Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) (GlobeNewswire)
Mar-07-25 02:10PM	Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules (GlobeNewswire) -19.44%
Feb-18-25 05:52PM	Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025 (Newsfile) -8.47%
Feb-14-25 07:30AM	Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Feb-04-25 09:15AM	Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board (GlobeNewswire) +10.87%
Jan-23-25 07:30AM	Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea (GlobeNewswire) -11.95%
Dec-02-24 04:48PM	Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025 (Newsfile)
Nov-14-24 04:05PM	Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates (GlobeNewswire) -11.70% -14.53%
Oct-24-24 07:30AM	Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer (GlobeNewswire)
Oct-02-24 04:50PM	Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL) (Newsfile)
Sep-30-24 04:01PM	Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates (GlobeNewswire) -15.58%
Sep-10-24 08:00AM	Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors (GlobeNewswire)
Sep-09-24 08:00AM	Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives (Newsfile)
Aug-05-24 07:30AM	FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed (GlobeNewswire) +11.11%
Jul-30-24 07:30AM	Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X (GlobeNewswire) -11.37%
Jul-01-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jun-27-24 07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -13.64%
May-30-24 07:30AM	Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea (GlobeNewswire)
May-07-24 07:30AM	Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder (GlobeNewswire)
May-01-24 02:33PM	Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD) (Newsfile) -7.61%
Apr-16-24 08:00AM	Incannex Healthcare Inc. Quarterly Update, Q1 2024 (GlobeNewswire) -8.30%
Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Feb-28-24 07:30AM	Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder (GlobeNewswire) +48.58%
Feb-16-24 07:30AM	Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation (GlobeNewswire) +5.68%
Feb-01-24 07:30AM	Clarion Clinics Open for Psychedelic-Assisted Treatments (GlobeNewswire) -6.40%
Jan-24-24 04:05PM	Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis (GlobeNewswire)
Jan-18-24 08:22AM	Incannex Completes Dosing and Therapy in Phase 2 PsiGAD Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences (GlobeNewswire)
Jan-17-24 07:30AM	Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea (GlobeNewswire)
Dec-21-23 04:05PM	Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia (GlobeNewswire) +5.08%
Dec-06-23 07:30AM	Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea (GlobeNewswire) -22.45%
Nov-29-23 01:40PM	Incannex Healthcare Announces Completion of its Redomiciliation to the United States (GlobeNewswire)
Nov-16-23 08:30AM	Federal Court of Australia Approves Incannex's Re-Domiciliation and Lodgement of Court Orders With ASIC (GlobeNewswire) -12.24%
Sep-08-23 07:30AM	Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023 (GlobeNewswire) +5.56%
Aug-24-23 01:15PM	Incannex preparing psilocybin therapy FDA IND application (News Direct)
07:30AM	Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD (GlobeNewswire)
Aug-23-23 11:45AM	Incannex full steam ahead towards sleep apnoea trial (News Direct)
Aug-22-23 07:30AM	Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed (GlobeNewswire)
Aug-08-23 08:00AM	Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening (GlobeNewswire)
Jul-28-23 07:30AM	Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement (GlobeNewswire)
Jul-27-23 01:20PM	Incannex thrilled with positive pre-IND meeting for arthritis treatment (News Direct)
Jul-26-23 07:30AM	Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis (GlobeNewswire)
Jul-21-23 09:09AM	Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea (GlobeNewswire)
Jul-18-23 02:30PM	Incannex appoints CRO ahead of Phase 2/3 sleep apnoea trial (News Direct)
07:40AM	Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea (GlobeNewswire)
Jul-13-23 08:00AM	Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis (GlobeNewswire)
Jul-11-23 03:00PM	Incannex CEO talks plans to redomicile to US (News Direct)
Jul-10-23 07:30AM	Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq (GlobeNewswire) +6.25%
Jul-06-23 08:42AM	Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Companys Proprietary Drug for Treatment of Obstructive Sleep Apnoea (OSA) (GlobeNewswire) +13.44%
Jun-23-23 08:00AM	Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023 (GlobeNewswire)
Jun-19-23 11:20AM	Incannex appoints principal investigators for pivotal IHL-42X trial (News Direct)
Jun-16-23 08:00AM	Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial (GlobeNewswire)
Jun-01-23 12:15PM	Incannex welcomes world-leading psychedelics experts to advisory board (News Direct)
May-30-23 08:00AM	World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board (GlobeNewswire)
May-16-23 07:50AM	Incannex Company Presentation Presentation of Psychennex, Psychedelic Therapies Subsidiary Company (GlobeNewswire)
May-05-23 07:30AM	Incannex enters a lease for first psychedelic-assisted psychotherapy clinic (GlobeNewswire)
May-03-23 02:20PM	Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A (News Direct)
07:30AM	Incannex Company Presentation Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A (GlobeNewswire)

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

PresidentMr. Joel Bradley Latham

CFOMr. Joseph Swan

Chief Medical OfficerDr. Luigi M. Barbato M.D.

CTO & Member of Advisory BoardMr. Lekhram Changoer M.Sc.

Chief Scientific OfficerDr. Mark Bleackley Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Incannex Healthcare Inc

Upgrade your Finviz experience